Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 2
1964 1
1965 1
1966 2
1967 2
1968 3
1969 4
1970 8
1971 8
1972 7
1973 4
1974 8
1975 6
1976 8
1977 5
1978 10
1979 7
1980 9
1981 7
1982 6
1983 8
1984 6
1985 16
1986 15
1987 12
1988 9
1989 12
1990 12
1991 18
1992 15
1993 17
1994 16
1995 20
1996 18
1997 16
1998 21
1999 28
2000 25
2001 19
2002 31
2003 27
2004 37
2005 33
2006 31
2007 45
2008 42
2009 50
2010 42
2011 43
2012 52
2013 55
2014 64
2015 72
2016 78
2017 70
2018 67
2019 74
2020 67
2021 56
2022 52
2023 47
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

1,408 results

Results by year

Filters applied: . Clear all
Page 1
Targeting CD47 for cancer immunotherapy.
Jiang Z, Sun H, Yu J, Tian W, Song Y. Jiang Z, et al. J Hematol Oncol. 2021 Oct 30;14(1):180. doi: 10.1186/s13045-021-01197-w. J Hematol Oncol. 2021. PMID: 34717705 Free PMC article. Review.
Majority of the CD47-related clinical trials are at the early phases, such as 31 at phase I, 14 at phase II and 1 at phase III in the USA and 9, 6, 1, in China, respectively. ...The new generation CD47 antibodies have demonstrated promising results, and it is highly hopefu …
Majority of the CD47-related clinical trials are at the early phases, such as 31 at phase I, 14 at phase II and 1 at phase III in the …
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Balleyguier C, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bardet A, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Archambaud B, Duffaud F; French Sarcoma Group. Pautier P, et al. Lancet Oncol. 2022 Aug;23(8):1044-1054. doi: 10.1016/S1470-2045(22)00380-1. Epub 2022 Jul 11. Lancet Oncol. 2022. PMID: 35835135 Clinical Trial.
We aimed to identify and compare the progression-free survival of patients with metastatic or unresectable uterine or soft tissue leiomyosarcoma treated with doxorubicin and trabectedin combined as first-line therapy versus doxorubicin alone in a phase 3 trial. METH …
We aimed to identify and compare the progression-free survival of patients with metastatic or unresectable uterine or soft tissue leiomyo …
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Demetri GD, et al. J Clin Oncol. 2016 Mar 10;34(8):786-93. doi: 10.1200/JCO.2015.62.4734. Epub 2015 Sep 14. J Clin Oncol. 2016. PMID: 26371143 Free PMC article. Clinical Trial.
PURPOSE: This multicenter study, to our knowledge, is the first phase III trial to compare trabectedin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior therapy with an anthracycline and at least one additional systemic regimen. …
PURPOSE: This multicenter study, to our knowledge, is the first phase III trial to compare trabectedin versus dacarbazine in patients …
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Marth C, Tarnawski R, Tyulyandina A, Pignata S, Gilbert L, Kaen D, Rubio MJ, Frentzas S, Beiner M, Magallanes-Maciel M, Farrelly L, Choi CH, Berger R, Lee C, Vulsteke C, Hasegawa K, Braicu EI, Wu X, McKenzie J, Lee JJ, Makker V. Marth C, et al. Int J Gynecol Cancer. 2022 Jan;32(1):93-100. doi: 10.1136/ijgc-2021-003017. Epub 2021 Nov 19. Int J Gynecol Cancer. 2022. PMID: 34799418 Free PMC article.
In a randomized phase 3 trial of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer (KEYNOTE-775/Study 309), after 1-2 previous lines of therapy (including neoadjuvant/adjuvant), this comb …
In a randomized phase 3 trial of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patien …
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Schöffski P, et al. Lancet. 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. Epub 2016 Feb 10. Lancet. 2016. PMID: 26874885 Free article. Clinical Trial.
BACKGROUND: A non-randomised, phase 2 study showed activity and tolerability of eribulin in advanced or metastatic soft-tissue sarcoma. ...Randomisation was stratified by disease type, geographical region, and number of previous regimens for advanced soft-tissue sar …
BACKGROUND: A non-randomised, phase 2 study showed activity and tolerability of eribulin in advanced or metastatic soft-tissue sarcom …
Uterine sarcoma 2008.
Lin JF, Slomovitz BM. Lin JF, et al. Curr Oncol Rep. 2008 Nov;10(6):512-8. doi: 10.1007/s11912-008-0077-9. Curr Oncol Rep. 2008. PMID: 18928666 Review.
Adjuvant therapies, including radiation, chemotherapy, and/or hormonal therapy, have limited benefit on overall survival; however, this may be due to the lack of good randomized controlled trials of sufficient size because of uterine sarcomas' rare and aggressive nature. F …
Adjuvant therapies, including radiation, chemotherapy, and/or hormonal therapy, have limited benefit on overall survival; however, this may …
Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patients.
Turinetto M, Meeus P, Ray-Coquard I. Turinetto M, et al. Curr Opin Oncol. 2023 Jul 1;35(4):288-291. doi: 10.1097/CCO.0000000000000961. Epub 2023 May 18. Curr Opin Oncol. 2023. PMID: 37222199 Review.
PURPOSE OF REVIEW: Currently, the only systemic therapy approved for advanced leiomyosarcoma is Doxorubicin-based monotherapy. Despite disappointing progression-free survival (PFS) and overall survival (OS), no combination therapy has formally ever proven to be more effect …
PURPOSE OF REVIEW: Currently, the only systemic therapy approved for advanced leiomyosarcoma is Doxorubicin-based monotherapy. Despit …
Eribulin in advanced liposarcoma and leiomyosarcoma.
Setola E, Noujaim J, Benson C, Chawla S, Palmerini E, Jones RL. Setola E, et al. Expert Rev Anticancer Ther. 2017 Aug;17(8):717-723. doi: 10.1080/14737140.2017.1344098. Epub 2017 Jun 28. Expert Rev Anticancer Ther. 2017. PMID: 28621163 Review.
Areas covered: Eribulin has recently been approved for advanced liposarcoma, after an anthracycline-containing regimen, demonstrating an overall survival (OS) advantage in liposarcoma and leiomyosarcoma in a randomised Phase III clinical trial. In this …
Areas covered: Eribulin has recently been approved for advanced liposarcoma, after an anthracycline-containing regimen, demonstrating an ove …
Options for Adjuvant Therapy for Uterine Leiomyosarcoma.
Friedman CF, Hensley ML. Friedman CF, et al. Curr Treat Options Oncol. 2018 Feb 8;19(2):7. doi: 10.1007/s11864-018-0526-0. Curr Treat Options Oncol. 2018. PMID: 29417238 Review.
However, heterogeneous patient populations, small sample sizes, and lack of no-treatment control arms have limited the interpretation and reliability of the results from these studies. A randomized trial of adjuvant pelvic radiation compared to no additional treatme …
However, heterogeneous patient populations, small sample sizes, and lack of no-treatment control arms have limited the interpretation and re …
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Gronchi A, et al. Lancet Oncol. 2017 Jun;18(6):812-822. doi: 10.1016/S1470-2045(17)30334-0. Epub 2017 May 9. Lancet Oncol. 2017. PMID: 28499583 Clinical Trial.
We aimed to show the superiority of the neoadjuvant administration of histotype-tailored regimen to standard chemotherapy. METHODS: For this international, open-label, randomised, controlled, phase 3, multicentre trial, patients were enrolled from 32 hospitals in It …
We aimed to show the superiority of the neoadjuvant administration of histotype-tailored regimen to standard chemotherapy. METHODS: For this …
1,408 results